Department of Ophthalmology, National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan, Republic of China.
Eye (Lond). 2010 Apr;24(4):547-52. doi: 10.1038/eye.2009.181. Epub 2009 Jul 24.
To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation in Asian patients with refractory glaucoma.
The study was a retrospective interventional case series conducted at a single institution between January 2004 and January 2006. The study population included 91 patients (91 eyes).
A total of 70 patients were successfully treated (74.5%). Postoperatively, the median intraocular pressures declined significantly to 13 mm Hg (interquartile range: 10-20 mm Hg) on day 1 (P<0.001) and 17 mm Hg (interquartile range: 12-19 mm Hg) at the last follow-up examination (P<0.001). The cumulative probability of success according to Kaplan-Meier life-table analysis was 74% at 12 months and 43% at 2 years. Hazard of failure increased slightly with age, HR: 1.03 (95% confidence interval (CI)=1.00-1.05; P=0.044). The most common complication was hyphaemia at 12.77%. There were no serious complications involving loss of visual acuity or sight.
AGV implantation is an acceptable treatment for refractory glaucoma in high-risk patients with few additional options.
评估 Ahmed 青光眼引流阀（AGV）植入术治疗亚洲难治性青光眼患者的疗效和安全性。
本研究为单中心回顾性介入病例系列研究，于 2004 年 1 月至 2006 年 1 月进行。研究人群包括 91 例（91 只眼）患者。
共 70 例患者（74.5%）成功治疗。术后第 1 天，中位眼内压显著下降至 13mmHg（四分位距：10-20mmHg）（P<0.001），末次随访时下降至 17mmHg（四分位距：12-19mmHg）（P<0.001）。Kaplan-Meier 生存表分析的累积成功率为 12 个月时 74%，2 年时 43%。失败风险随年龄略有增加，HR：1.03（95%置信区间（CI）=1.00-1.05；P=0.044）。最常见的并发症是 12.77%的菌血症。无视力丧失或失明等严重并发症。
AGV 植入术是治疗高危、治疗选择有限的难治性青光眼患者的一种可接受的方法。
